451 related articles for article (PubMed ID: 10498591)
1. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
Winkler U; Jensen M; Manzke O; Schulz H; Diehl V; Engert A
Blood; 1999 Oct; 94(7):2217-24. PubMed ID: 10498591
[TBL] [Abstract][Full Text] [Related]
2. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.
Maeda T; Yamada Y; Tawara M; Yamasaki R; Yakata Y; Tsutsumi C; Onimaru Y; Kamihira S; Tomonaga M
Int J Hematol; 2001 Jul; 74(1):70-5. PubMed ID: 11530808
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
5. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.
Huhn D; von Schilling C; Wilhelm M; Ho AD; Hallek M; Kuse R; Knauf W; Riedel U; Hinke A; Srock S; Serke S; Peschel C; Emmerich B;
Blood; 2001 Sep; 98(5):1326-31. PubMed ID: 11520778
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
[TBL] [Abstract][Full Text] [Related]
8. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
[TBL] [Abstract][Full Text] [Related]
9. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
10. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
12. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).
Jensen M; Winkler U; Manzke O; Diehl V; Engert A
Ann Hematol; 1998; 77(1-2):89-91. PubMed ID: 9760161
[TBL] [Abstract][Full Text] [Related]
13. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.
Pickartz T; Ringel F; Wedde M; Renz H; Klein A; von Neuhoff N; Dreger P; Kreuzer KA; Schmidt CA; Srock S; Schoeler D; Schriever F
Exp Hematol; 2001 Dec; 29(12):1410-6. PubMed ID: 11750099
[TBL] [Abstract][Full Text] [Related]
14. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; Bodkin DJ; White CA; Liles TM; Royston I; Varns C; Rosenberg J; Levy R
J Clin Oncol; 1997 Oct; 15(10):3266-74. PubMed ID: 9336364
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
16. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
Byrd JC; Murphy T; Howard RS; Lucas MS; Goodrich A; Park K; Pearson M; Waselenko JK; Ling G; Grever MR; Grillo-Lopez AJ; Rosenberg J; Kunkel L; Flinn IW
J Clin Oncol; 2001 Apr; 19(8):2153-64. PubMed ID: 11304767
[TBL] [Abstract][Full Text] [Related]
17. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.
Ladetto M; Bergui L; Ricca I; Campana S; Pileri A; Tarella C
Med Oncol; 2000 Aug; 17(3):203-10. PubMed ID: 10962531
[TBL] [Abstract][Full Text] [Related]
18. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Schulz H; Klein SK; Rehwald U; Reiser M; Hinke A; Knauf WU; Aulitzky WE; Hensel M; Herold M; Huhn D; Hallek M; Diehl V; Engert A;
Blood; 2002 Nov; 100(9):3115-20. PubMed ID: 12384407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
